Evidence map›Paper›PMID 42754561›Full record

ArticleNature communications2026

Clonal sharing and plasticity of follicular CD4 + T cells across lymph nodes and tumors in non-small cell lung cancer.

Jimena Tosello Boari, Wilfrid Richer, Yoann Missolo-Koussou, Elisa Bonnin, Sebastien Lemoine, Marco Antônio Pretti, Rodrigo Nalio Ramos, Jeremy Mesple, Jordan Denizeau, Sylvain Baulande and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Jimena Tosello Boari *INSERM U932, PSL University, Institut Curie Research Center, Paris, France.
Wilfrid Richer *INSERM U932, PSL University, Institut Curie Research Center, Paris, France.
Yoann Missolo-KoussouDepartment of Translational Research, PSL University, Institut Curie Research Center, Paris, France.ORCID http://orcid.org/0000-0002-3815-3980
Elisa BonninINSERM U932, PSL University, Institut Curie Research Center, Paris, France.
Sebastien LemoineEgle Therapeutics, Paris, France.
Marco Antônio PrettiEgle Therapeutics, Paris, France.
Rodrigo Nalio RamosINSERM U932, PSL University, Institut Curie Research Center, Paris, France.ORCID http://orcid.org/0000-0003-1249-4733
Jeremy MespleINSERM U932, PSL University, Institut Curie Research Center, Paris, France.
Jordan DenizeauINSERM U932, PSL University, Institut Curie Research Center, Paris, France.
Sylvain BaulandeInstitut Curie, PSL University, ICGex Next-Generation Sequencing Platform, Paris, France.ORCID http://orcid.org/0000-0003-3104-1684
Mylène BohecInstitut Curie, PSL University, ICGex Next-Generation Sequencing Platform, Paris, France.ORCID http://orcid.org/0000-0002-6530-596X
Sonia LameirasInstitut Curie, PSL University, ICGex Next-Generation Sequencing Platform, Paris, France.
Philippe MartinDepartment of Translational Research, PSL University, Institut Curie Research Center, Paris, France.
Rafael Mena OsunaINSERM U932, PSL University, Institut Curie Research Center, Paris, France.
Wenjie SunInstitut Curie, Université PSL, Sorbonne Université, CNRS UMR168, Physique des Cellules et Cancer, Paris, France.ORCID http://orcid.org/0000-0002-3100-2346
Marine LefevreInstitut Montsouris, Pathology Department, Institut du Thorax Curie Montsouris, Paris, France.
Agathe Seguin-GiveletInstitut Montsouris, Surgery Department, Institut du Thorax Curie Montsouris, Paris, France.ORCID http://orcid.org/0000-0002-2906-4433
Christine SedlikINSERM U932, PSL University, Institut Curie Research Center, Paris, France.ORCID http://orcid.org/0000-0001-8502-0905
Filipa RamosGulbenkian Institut for Molecular Medicine, Lisbon, Portugal.
Saumya KumarGulbenkian Institut for Molecular Medicine, Lisbon, Portugal.
Leïla PeriéInstitut Curie, Université PSL, Sorbonne Université, CNRS UMR168, Physique des Cellules et Cancer, Paris, France.ORCID http://orcid.org/0000-0003-0798-4498
Luis GraçaGulbenkian Institut for Molecular Medicine, Lisbon, Portugal.ORCID http://orcid.org/0000-0001-6935-8500
Olivier LantzINSERM U932, PSL University, Institut Curie Research Center, Paris, France.ORCID http://orcid.org/0000-0003-3161-7719
Edith BorcomanINSERM U932, PSL University, Institut Curie Research Center, Paris, France.ORCID http://orcid.org/0000-0002-5393-5657
Nicolas GirardInstitut Curie, Institut du Thorax Curie Montsouris, Paris, France.
Joshua J WaterfallDepartment of Translational Research, PSL University, Institut Curie Research Center, Paris, France. joshua.waterfall@curie.fr.ORCID http://orcid.org/0000-0002-3762-5050
Eliane PiaggioINSERM U932, PSL University, Institut Curie Research Center, Paris, France. eliane.piaggio@curie.fr.ORCID http://orcid.org/0000-0002-2455-8442

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor-invaded lymph nodes (LNs) are critical but poorly studied hubs of anti-tumor immunity. Using single-cell transcriptome, clonotype, and chromatin profiling, we analyze CD4 + T cells from blood, LNs, and tumors of NSCLC patients. LNs and tumors are enriched in follicular regulatory T cells (Treg-Tfr), follicular-like conventional T cells (Tconv-Tfh and Tconv-CXCL13), and tissue-resident Tregs (Treg-Trm). These populations are predicted to share a transcriptional program of activation and tissue adaptation, driven by BATF. Additionally, these subsets show extensive LN-tumor clonal sharing, indicating recirculation, and are enriched in transcriptional signatures of tumor reactivity. Treg-Tfr cells function as progenitors bifurcating into Treg-Trm or ex-Tregs with a Tfh-like CXCL13+ effector phenotype. Follicular subsets in LNs and tumors are transcriptionally and epigenetically similar and localize in germinal-center-like niches. Overall, tumor-invaded LNs and tumors coordinate the generation and maintenance of tumor-reactive CD4+ lineages, identifying highly plastic follicular T cells as therapeutic checkpoints to reinforce anti-tumor responses.

Indexed as

Carcinoma, Non-Small-Cell LungCD4-Positive T-LymphocytesLung NeoplasmsLymph NodesAnimalsCell PlasticityFemaleGerminal CenterHumansMiceT-Lymphocytes, Regulatory

Identifiers

PMID42754561
PMCPMC13586225

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.